Overview
COCH market data
Price History
COCH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.98 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.2% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,875.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.36 – $1.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $57.6M · P/S 246.20.
Company News
Envoy Medical Expects To Submit Four Modules, Final Module Of PMA Application Targeted For Submission In Q2 2027Benzinga · Aug 10, 2026, 9:00 PM
Envoy Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $51.000K Miss $80.000K EstimateBenzinga · Aug 10, 2026, 12:15 PM
LUCID CAPITAL MARKETS Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $2Benzinga · Jul 27, 2026, 12:07 PM
EXCLUSIVE: Envoy Medical Completes 3-Month Follow-Ups For All 56 Trial Patients, Advancing Its Fully Implanted Acclaim Cochlear Implant Toward FDA submission; 12-Month Visit Milestone Expected By April 2027Benzinga · Jul 21, 2026, 1:00 PM
EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear ImplantBenzinga · Jul 21, 2026, 1:00 PM
HC Wainwright & Co. Reiterates Buy on Envoy Medical, Maintains $2.5 Price TargetBenzinga · Jul 15, 2026, 11:45 AM
Envoy Medical shares are trading higher after the company announced 12‑month Stage 1 data from its Acclaim cochlear implant trial, showing continued improvement in word recognition.Benzinga · Jul 14, 2026, 5:02 PM
EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial ResultsBenzinga · Jul 14, 2026, 1:01 PM
EXCLUSIVE: Envoy Medical Says 12-Month Data Shows Continued Improvement in Word Recognition in Ear Implant StudyBenzinga · Jul 14, 2026, 1:01 PM
Envoy Medical Submits First Module Of Modular Premarket Approval Application To FDA For Breakthrough Device-Designated Product; Co Plans Four Module Submissions, Final Data Filing Targeted Q2 2027Benzinga · Jun 30, 2026, 12:50 PM